SARS-CoV-2 vaccine strategies in kidney transplant recipients

Conventional vaccine strategies against SARS-CoV-2 can be insufficient to generate immunological responses to vaccine or provide protection from COVID-19 in kidney transplant recipients (KTRs). In this group, vulnerability to infection remains high. In contrast to the general population, in which there is good evidence for booster doses of mRNA vaccine leading to enhanced immunological responses and protection from infection, a significant proportion of KTRs do not benefit from third or even fourth vaccine doses. In KTRs, and other patients who are immunosuppressed, investigation of modified vaccination strategies is needed to potentially enhance protection of this vulnerable group.

Author list



Centre for Inflammatory Disease, Department of Immunology and Inflammation, Imperial College London, Hammersmith Campus, Du Cane Road, London W12 0NN, UK


Maria Prendecki, Michelle Willicombe

Novel Coronavirus SARS-CoV-2


Lancet - Infectious Diseases